Features and Benefits
Amongst many benefits of the Intellomx technology is the ability to identify pathways and drivers of disease progression which can help develop new and targeted therapies.
Intellomx technology also offers a significant benefit in being able to rapidly screen large numbers of proteomic, genomic, metaboloimic or transcriptomic biomarkers, using non-linear Insilico methods, to identify biomarkers (singular or in panels) that address biomedical, physiological and clinical questions in molecular data.
This approach can also identify molecular drivers associated with clinical physiological features, specific to the disease population being analysed. The markers identified by these approaches have been shown to have excellent biological relevance and high sensitivity and specificity both for seen and new unseen populations.
Cost and Time Savings
Intellomx technology offers considerable commercial advantages in terms of cost and time. The Insilico approach allows screening of millions of molecular combinations and interactions without the need for extensive wet lab time and costs, “wet lab work” only being require being for validation of the final small selected panel of markers.
Intellomx has developed methods that have greatly reduced the computational time required for analysis from weeks to days or even hours, enabling it to handle the ever increasing sizes of data sets.
A further benefit, from a commercial viewpoint, is that over 50% of the markers identified are classed as novel biomarkers, not previously associated with the condition under study, leading to the opportunity for the development of patentable IP.
Accelerating the Drug Discovery Processs
Intellomx can also utilise the findings of its Artificial Neural Networks (ANNs) to identify with strong probability potential new chemical entities or repurposed drugs which act on key molecular drivers for a given disease state. This can supercede months and years of wet lab R&D to yield new drugs associated with novel druggable entities.